Figure 2.
OS, PFS, and time to NT. Outcome visualized as Kaplan-Meier curves on the intention to treat population (n = 225) for (A): OS, (B) PFS, and (C) time to NT from start of treatment. Landmark analyses for (D) OS, (E) PFS, and (F) NT are presented from time point of randomization at end of cycle 15 for arm A, ibrutinib maintenance; arm B, treatment cessation; and the nonrandomized arm.